ebastine

Ebastine is a H1 antihistamine with low potential for causing drowsiness.

Key facts

Drug.verifiedrevid: 439227374
Drug.IUPAC_name: 4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one
Drug.image: Ebastine.svg
Drug.image_class: skin-invert-image
Drug.caption: Above: molecular structure of ebastine Below: 3D representation of an ebastine molecule
Drug.image2: Ebastine 3D.png
Drug.image_class2: bg-transparent
Drug.routes_of_administration: Oral
Drug.protein_bound: Greater than 95%
Drug.metabolism: Hepatic (CYP3A4-mediated), to carebastine
Drug.elimination_half life: 15 to 19 hours (carebastine)
Drug.CAS_number: 90729-43-4
Drug.ATC_prefix: R06
Drug.ATC_suffix: AX22
Drug.PubChem: 3191
Drug.ChemSpiderID: 3079
Drug.UNII: TQD7Q784P1
Drug.ChEMBL: 305660

via Wikipedia infobox

Chemical data

Formula: C32H39NO2
Molecular weight: 469.7 g/mol
IUPAC name: 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
SMILES: CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
InChIKey: MJJALKDDGIKVBE-UHFFFAOYSA-N
XLogP: 7.2
Polar surface area: 29.5 Å²
H-bond donors: 0
H-bond acceptors: 3
Formal charge: 0

via PubChem

Research

398 papers

Ebastine.2006
Ebastine: an update of its use in allergic disorders.Drugs · 2000
Ebastine in allergic rhinitis and chronic idiopathic urticaria.Allergy · 2008
Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience.Journal of investigational allergology & clinical immunology · 2020
Cardiac effects of ebastine and other antihistamines in humans.Drug safety · 1999

via PubMed

Wikidata facts

Mass: 469.298

Show 4 more facts

chemical formula: C₃₂H₃₉NO₂
canonical SMILES: CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
defined daily dose: 10
Commons category: Ebastine

Sources (3)

via Wikidata · CC0

~2 min read

Article

7 sections

Contents

Uses
Safety
Pharmacokinetic profile
Brand names
See also
References
External links

Ebastine is a H1 antihistamine with low potential for causing drowsiness.

It does not penetrate the blood–brain barrier to a significant amount and thus combines an effective block of the H1 receptor in peripheral tissue with a low incidence of central side effects, i.e. seldom causing sedation or drowsiness.